Fig. 4: OS of real-world teclistamab in subgroups.

A OS according to prior BCMA exposure. B OS according to the type of prior BCMA-directed agent. C OS according to cytogenetic risk. D OS according to creatinine clearance. E OS according to penta-drug refractoriness. F OS according to MajesTEC-1 eligibility.